Droplet Biosciences has developed a platform to harvest and profile patient lymph fluid collected from surgical drains. This approach provides enhanced access to the tumor microenvironment near the surgical site for superior local assessment of cancer recurrence risk. The resulting lymph liquid biopsy enables earlier, more precise adjuvant decision-making following cancer surgery.
Funding
$18.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
TEFounders
Product
Problem
Post-operative monitoring for cancer recurrence relies on infrequent imaging and blood-based biopsies, which may lack sensitivity to detect early signs of metastasis. Current methods often fail to capture the complexity of the tumor microenvironment and may delay critical treatment decisions. Accessing patient lymph fluid for routine analysis has historically been infeasible, limiting diagnostic capabilities.
Solution
Droplet Biosciences has developed a platform to harvest and analyze lymphatic fluid collected from surgical drains, providing a novel approach to liquid biopsy. By concentrating lymphatic fluid, Droplet offers an enhanced view into the tumor microenvironment, enabling superior local assessment of recurrence risk. The platform facilitates the routine collection of patient lymph, which was previously unattainable, allowing for earlier and more precise post-operative care. Their lymph liquid biopsy enables healthcare professionals to make informed adjuvant treatment decisions sooner, potentially improving patient outcomes. The company's expansive lymph dataset also offers novel insights into patient selection and treatment response.
Target Audience
The primary target audience includes oncologists, surgeons, and healthcare professionals involved in post-operative cancer care and recurrence monitoring.
Features
- Platform for harvesting and profiling lymphatic fluid from surgical drain collections.
- Concentration of lymphatic fluid to enhance visibility into the tumor microenvironment.
- Local assessment of recurrence risk due to proximity to the tumor site.
- Biomarker analysis of lymphocytes, proteins, and other molecules present in lymph fluid.
- Liquid biopsy technique using lymph fluid as a non-invasive alternative to traditional methods.
- Data analysis and insights related to patient selection and treatment response.